肿瘤微环境胶原特征与早期胃癌淋巴结转移的关联
该回顾性研究基于中国两家中心共375例早期胃癌根治术后患者,利用多光子成像提取肿瘤微环境胶原特征并构建淋巴结转移预测模型。胶原特征与淋巴结转移显著相关(OR 5.470,95%CI 3.315-9.026,P<.001),联合浸润深度和分化程度建立列线图,主队列和验证队列AUROC分别为0.955和0.938。
要点
- 胶原特征为早期胃癌淋巴结转移的独立预测因子(OR 5.470,P<.001)。
- 联合浸润深度、分化程度和胶原特征的列线图区分度良好(AUROC 0.955/0.938)。
- 模型阴性预测值达97%以上,可能有助于筛选可避免淋巴结清扫的患者。
核心结论
- 肿瘤微环境胶原特征是早期胃癌淋巴结转移的独立指标,基于此的预测模型可能有助于治疗决策。
研究设计与样本
- 回顾性研究,2016年8月1日至2018年5月10日在中国两家医疗中心(南方医院和福建省立医院)开展。
- 主队列为2008年1月1日至2012年12月31日连续232例T1胃癌根治术后患者,排除接受新辅助放化疗者。
- 验证队列为2011年1月1日至2013年12月31日连续143例相同诊断患者,共纳入375例。
- 利用多光子成像提取标本胶原特征并构建胶原特征,开发淋巴结转移预测模型并进行内部和外部验证。
主要发现
- 主队列淋巴结转移率16.4%(38/232;男性25例[65.8%],平均年龄57.82[10.17]岁)。
- 验证队列淋巴结转移率20.9%(30/143;男性20例[66.7%],平均年龄54.10[13.19]岁)。
- 胶原特征与淋巴结转移显著相关(OR 5.470;95%CI 3.315-9.026;P<.001)。
- 多因素分析显示浸润深度、肿瘤分化和胶原特征为淋巴结转移的独立预测因子,三者纳入新预测模型并建立列线图。
- 主队列AUROC 0.955(95%CI 0.919-0.991),验证队列AUROC 0.938(95%CI 0.897-0.981)。
关键数值与推荐
- 主队列最佳截断值:灵敏度86.8%,特异度93.3%,准确率92.2%,阳性预测值71.7%,阴性预测值97.3%。
- 验证队列:灵敏度90.0%,特异度90.3%,准确率90.2%,阳性预测值71.1%,阴性预测值97.1%。
- 全部375例:灵敏度87.3%,特异度92.1%,准确率91.2%,阳性预测值72.1%,阴性预测值96.9%。
临床怎么用
- 对于早期胃癌患者,可基于肿瘤微环境胶原特征联合浸润深度和分化程度评估淋巴结转移风险。
- 模型高阴性预测值可能辅助识别淋巴结转移低风险患者,为个体化治疗决策提供参考。
局限性
- 回顾性研究设计,样本来自两家医疗中心,外推性需进一步验证。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Lymph node status is the primary determinant in treatment decision making in early gastric cancer (EGC). Current evaluation methods are not adequate for estimating lymph node metastasis (LNM) in EGC. OBJECTIVE: To develop and validate a prediction model based on a fully quantitative collagen signature in the tumor microenvironment to estimate the individual risk of LNM in EGC. DESIGN, SETTING, AND PARTICIPANTS: This retrospective study was conducted from August 1, 2016, to May 10, 2018, at 2 medical centers in China (Nanfang Hospital and Fujian Provincial Hospital). Participants included a primary cohort (n = 232) of consecutive patients with histologically confirmed gastric cancer who underwent radical gastrectomy and received a T1 gastric cancer diagnosis from January 1, 2008, to December 31, 2012. Patients with neoadjuvant radiotherapy, chemotherapy, or chemoradiotherapy were excluded. An additional consecutive cohort (n = 143) who received the same diagnosis from January 1, 2011, to December 31, 2013, was enrolled to provide validation. Baseline clinicopathologic data of each patient were collected. Collagen features were extracted in specimens using multiphoton imaging, and the collagen signature was constructed. An LNM prediction model based on the collagen signature was developed and was internally and externally validated. MAIN OUTCOMES AND MEASURES: The area under the receiver operating characteristic curve (AUROC) of the prediction model and decision curve were analyzed for estimating LNM. RESULTS: In total, 375 patients were included. The primary cohort comprised 232 consecutive patients, in whom the LNM rate was 16.4% (n = 38; 25 men [65.8%] with a mean [SD] age of 57.82 [10.17] years). The validation cohort consisted of 143 consecutive patients, in whom the LNM rate was 20.9% (n = 30; 20 men [66.7%] with a mean [SD] age of 54.10 [13.19] years). The collagen signature was statistically significantly associated with LNM (odds ratio, 5.470; 95% CI, 3.315-9.026; P < .001). Multivariate analysis revealed that the depth of tumor invasion, tumor differentiation, and the collagen signature were independent predictors of LNM. These 3 predictors were incorporated into the new prediction model, and a nomogram was established. The model showed good discrimination in the primary cohort (AUROC, 0.955; 95% CI, 0.919-0.991) and validation cohort (AUROC, 0.938; 95% CI, 0.897-0.981). An optimal cutoff value was selected in the primary cohort, which had a sensitivity of 86.8%, a specificity of 93.3%, an accuracy of 92.2%, a positive predictive value of 71.7%, and a negative predictive value of 97.3%. The validation cohort had a sensitivity of 90.0%, a specificity of 90.3%, an accuracy of 90.2%, a positive predictive value of 71.1%, and a negative predictive value of 97.1%. Among the 375 patients, a sensitivity of 87.3%, a specificity of 92.1%, an accuracy of 91.2%, a positive predictive value of 72.1%, and a negative predictive value of 96.9% were found. CONCLUSIONS AND RELEVANCE: This study's findings suggest that the collagen signature in the tumor microenvironment is an independent indicator of LNM in EGC, and the prediction model based on this collagen signature may be useful in treatment decision making for patients with EGC.
引用
- Chen D, Chen G, Jiang W, et al. Association of the Collagen Signature in the Tumor Microenvironment With Lymph Node Metastasis in Early Gastric Cancer. JAMA Surg. 2019. PMID: 30698615. doi:10.1001/jamasurg.2018.5249
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。